ICON plc | Clinical Research Organisation (CRO) for Drug Development

Webinar: Integrating qualitative patient interviews into a clinical trial protocol

30 July, 11AM EST. Register now.

Webinar: Ensuring pharmacovigilance compliance and robust oversight

8 September, 11AM EST. Register now.

COVID-19: Navigating global market access requirements

Get recommendations to maxmise HTA success.

Pandemic respiratory vaccine clinical trials

Best practices to accelerate operations while the world waits.

Featured Services

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

01 July 2020

Juvenile Arthritis Awareness Month: This fight is personal

This blog is a condensed version of an ICON employee’s’ personal journey of courage and endurance.

24 June 2020

Enabling clinical development of cell and gene therapies on a global basis

In a recent podcast interview, ICON experts discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.

02 June 2020

Improving access and reimbursement for specialty therapies

Clinical development can better satisfy the evidence needs of payers, and not incorporating the needs of payers early into trial designs risks the need to spend more money later on.

29 May 2020

The differences between the US and EU biosimilar markets

Biosimilar uptake in the US market has, until now, stood in stark contrast to that in the EU, which has led the way in biosimilar approvals and use since 2006.

05 May 2020

How to ensure your trial data and patients remain safe during COVID-19

The COVID-19 pandemic has presented an array of cybersecurity challenges. With no slowing down of the virus’s spread, hackers and other cyber criminals are continuing to seize opportunities to take advantage of vulnerable networks.

29 April 2020

The impact of COVID-19 on pharmacovigilance

COVID-19 is affecting how clinical trials are managed, in terms of patient recruitment, patient care, data collection, analysis and safety reporting.

29 April 2020

Wearables and digital endpoint generation

The key considerations that arise when using digital technology to support endpoint generation in clinical studies.

27 April 2020

The shifting diagnostics regulatory landscape amid COVID-19

For IVD manufacturers, the emergence of a novel virus is challenging as the detection of such viruses require quickly developed, novel diagnostic solutions.

20 April 2020

Five common literature reviews for RWE generation

In the evidence-based era of medicine and decision-making, literature reviews offer a faster and more cost-efficient method to gather intelligence.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

COVID-19 clinical operations

Advancing digital endpoints

The role of estimands

Decentralised and hybrid clinical trials